LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Bio-Techne Corp

Slēgts

SektorsVeselības aprūpe

59.32 -2.29

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

59.02

Max

59.67

Galvenie mērījumi

By Trading Economics

Ienākumi

56M

38M

Pārdošana

-30M

287M

P/E

Sektora vidējais

117.265

105.69

EPS

0.53

Dividenžu ienesīgums

0.56

Peļņas marža

13.326

Darbinieki

3,100

EBITDA

71M

78M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+11% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.56%

2.37%

Nākamais dividenžu datums

2025. g. 28. nov.

Nākamais Ex dividenžu datums

2025. g. 17. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-585M

9B

Iepriekšējā atvēršanas cena

61.61

Iepriekšējā slēgšanas cena

59.32

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Bio-Techne Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. nov. 22:36 UTC

Peļņas

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Bio-Techne Corp Prognoze

Cenas mērķis

By TipRanks

11% augšup

Prognoze 12 mēnešiem

Vidējais 67.43 USD  11%

Augstākais 73 USD

Zemākais 60 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Bio-Techne Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

6

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

49.67 / 50.24Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Strong Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat